Thermo Fisher Scientific Inc. (TMO)
| Market Cap | 243.30B +20.2% |
| Revenue (ttm) | 46.34B +7.2% |
| Net Income | 6.97B +5.8% |
| EPS | 18.58 +7.4% |
| Shares Out | 369.75M |
| PE Ratio | 35.41 |
| Forward PE | 25.09 |
| Dividend | $1.88 (0.29%) |
| Ex-Dividend Date | Sep 15, 2026 |
| Volume | 1,580,678 |
| Open | 650.00 |
| Previous Close | 651.98 |
| Day's Range | 644.16 - 661.94 |
| 52-Week Range | 435.27 - 694.33 |
| Beta | 0.88 |
| Analysts | Strong Buy |
| Price Target | 677.24 (+2.92%) |
| Earnings Date | Oct 21, 2026 |
About TMO
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analy... [Read more]
Financial Performance
In 2025, Thermo Fisher's revenue was $44.56 billion, an increase of 3.91% compared to the previous year's $42.88 billion. Earnings were $6.70 billion, an increase of 5.82%.
Financial StatementsAnalyst Summary
According to 27 analysts, the average rating for TMO stock is "Strong Buy." The 12-month stock price target is $677.24, which is an increase of 2.92% from the latest price.
News
Thermo Fisher price target raised to $745 from $650 at BofA
BofA raised the firm’s price target on Thermo Fisher (TMO) to $745 from $650 and keeps a Buy rating on the shares. The life science tools sector has further re-rated…
Thermo Fisher price target raised to $750 from $650 at Barclays
Barclays analyst Luke Sergott raised the firm’s price target on Thermo Fisher (TMO) to $750 from $650 and keeps an Overweight rating on the shares. The firm adjusted targets in…
Quantum BioPharma signs contract with Thermo Fisher for sclerosis trial
Quantum BioPharma (QNTM) has entered into a Study Start-Up Agreement, or SUA, with the clinical research business of Thermo Fisher (TMO) to implement Quantum’s Phase 2 clinical trial of Lucid-21-302…
Thermo Fisher Scientific Showcases New Solutions and Expanded Capabilities to Accelerate Drug Development at CPHI Milan 2026
MILAN--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, is expanding its drug development, manufacturing, and clinical capabilities to help pharmaceutical and biotechnol...
Thermo Fisher Scientific Proteomics Technologies Enable Discovery of More Than 2,500 New Biological Associations in PRECISE-SG100K Study
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced that its strategic collaboration with Precision Health Research, Singapore (PRECISE...
JPMorgan Adds American Express, Liberty Energy, and Thermo Fisher to October Stock Picks List. Here’s Why.
JPMorgan ($JPM) refreshed its list of favorite stock ideas for October, adding five new companies across its value and growth strategies. The update follows a split September on Wall Street.
The Top HealthTech Questions Landing on Our Desks
Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled th...
Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 21, 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the third quarter 2026 before ...
Thermo Fisher price target raised to $720 from $635 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Thermo Fisher (TMO) to $720 from $635 and keeps a Buy rating on the shares following investor meetings, stating that ongoing execution,…
Thermo Fisher launches Gibco CHO-K1 Catalog Panel
Thermo Fisher (TMO) Scientific announced the Gibco CHO-K1 Catalog Panel, a cGMP-ready portfolio of basal and feed media designed to support strong cell growth and protein production across CHO-K1 cell...
Thermo Fisher Scientific Launches Gibco™ CHO-K1 Catalog Panel Media and Feed to Accelerate Biologics Development
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the Gibco™ CHO-K1 Catalog Panel, a cGMP-ready portfolio of basal and feed media designed...
Thermo Fisher Scientific Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Organic growth and EPS exceeded expectations, with strong momentum in pharma, biotech, and industrial markets. AI and reshoring trends are fueling multi-year growth, while strategic M&A and capacity expansions support long-term targets of 7% organic growth by 2028.
Uber initiated, Thermo Fisher upgraded: Wall Street’s top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by…
Thermo Fisher upgraded to Buy from Neutral at UBS
UBS upgraded Thermo Fisher (TMO) to Buy from Neutral with a price target of $730, up from $540, after assuming coverage of the name. Thermo Fisher is positioned for a…
Thermo Fisher upgraded to Buy from Neutral at UBS
UBS upgraded Thermo Fisher (TMO) to Buy from Neutral with a price target of $730, up from $540.
Thermo Fisher initiated with an Outperform at CLSA
CLSA analyst Michael Luo initiated coverage of Thermo Fisher (TMO) with an Outperform rating and $748 price target
Why Moderna's Cancer Vaccine Matters to Investors
Healthcare is moving away from the traditional model of mass-produced, one-size-fits-all treatments toward individualized therapies. This evolution in medicine aims to provide treatments that are not ...
Thermo Fisher Scientific Launches Multiskan™ Ease Absorbance Microplate Reader to Help Simplify Protein, Cell and Microbial Analysis
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific today announced the launch of the Thermo Scientific™ Multiskan™ Ease Absorbance Microplate Reader, designed to support protein quantification,...
Thermo Fisher Scientific to Present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman and chief executive officer, will present at th...
Thermo Fisher introduces Thermo Scientific EMPAD G2 detector
Thermo Fisher (TMO) Scientific introduced the Thermo Scientific EMPAD G2 detector, a new detector designed to help researchers see and understand materials in detail. EMPAD G2 enables high-speed four-...
Thermo Fisher Scientific Introduces the Thermo Scientific™ EMPAD™ G2 Electron Detector to Advance Materials Research
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Thermo Scientific™ EMPAD™ G2 detector, a new detector designed to help researc...
Thermo Fisher Scientific Launches First Orbitrap Mass Spectrometers for Isotope Ratio Analysis, Enabling More Labs to Decode the Story Behind a Sample
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today introduced the Thermo Scientific™ Orbitrap™ Isora™ Mass Spectrometer and Orbitrap Isora Pro Mass S...
Thermo Fisher complete sale of its microbiology business to Astorg for $1.075B
Thermo Fisher (TMO) Scientific announced that it has completed the sale of its microbiology business to Astorg for consideration of approximately $1.075B, consisting of cash and a $50M seller note.
Astorg Completes Acquisition of Microbiology Business From Thermo Fisher Scientific, Establishing an Independent Global Diagnostics Specialist
LUXEMBOURG & NEW YORK & PARIS--(BUSINESS WIRE)--Astorg, a leading pan-European private equity firm, today announced the successful completion of its acquisition of the global microbiology business fro...